majority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.
|
|
- Osborne Floyd
- 5 years ago
- Views:
Transcription
1 Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship and the role of chemotherapy, and specifically, androgen-deprivation therapy in prostate cancer. This will be a two part lecture. The objectives --- the objectives for today s talk are the following: upon completion of these lectures, the participant will be able to discuss the role of chemotherapy in localized and advanced prostate cancer. They should be able to state the indications for androgen-deprivation therapy, or ADT, in prostate cancer, and also recognize and manage short-term and long-term adverse events of androgen-deprivation therapy in men with prostate cancer. Chemotherapy has been tested for decades in the neoadjuvant and adjuvant trials of prostate cancer in the localized settings. Unfortunately, so far, we do not have convincing evidence that in localized prostate cancer there is any role in improving overall survival in men with prostate cancer. Therefore, chemotherapy is currently not recommended as a standard of care for early stage prostate cancer outside of clinical trials. We have many clinical trials ongoing that are re-addressing the issues currently, but, at this point, there is no recommendation for giving chemotherapy. In terms of more advanced disease, just as a sum --- an overall review, there are three cytotoxic agents approved for advanced castrate-resistant prostate cancer. Mitoxantrone is an anthracycline that was approved not based on survival benefit, but based on improvement of pain and other quality of life measures and basically relieves palliation. Docetaxel was tested in two large Phase 3 trials that were published in 2004 and compared to mitoxantrone. And both trials showed in men with advanced castrateresistant prostate cancer, a survival advantage of about two to three months. And based on these two trials, docetaxel was approved as an agent in metastatic prostate cancer. More recently, the TROPIC trial tested the role of cabazitaxel, a synthetic taxane, that was designed to overcome resistance to docetaxel in patients with metastatic castrate-resistant prostate cancer who had progressed or did not tolerate a prior docetaxel. And, again, there was a 2.4 months survival benefit when compared to mitoxantrone in this group. And, therefore, a cabazitaxel was approved as a secondline agent after docetaxel in men for castrate-resistant prostate cancer. Since the median survival for castrate-resistant metastatic prostate cancer unfortunately to date is around two years with very few long-term survivors and the objective of this talk is prostate cancer survivorship, I will, in the remaining slides, focus my talk on the long-term effects and management -andr --- of androgen-deprivation, rather than chemotherapy. ADT is the most important therapy in men with metastatic prostate cancer. It has been shown to improve bone pain in more than 80% of all patients. It does induce tumor shrinkage in lymph nodes and other soft tissue --- tissue metastatic disease in the
2 majority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival. It s clinically used in several settings. As mentioned, it is used as a palliative treatment in advanced prostate cancer and builds the baseline on which we build other therapies. But it s also an early stage disease combined with definitive external beam radiation therapy for localized high-risk or intermediate-risk prostate cancer. Studies randomized have shown overall survival benefit with six months of ADT in patients with med --- intermediate-risk disease and overall survival benefit when ADT is combined for three years with external beam radiation in patients with high-risk disease. Selection of men with high-risk features who undergo salvage radiotherapy after initial prostatectomy might also benefit from addition of ADT to their salvage radiation. And possibly, men with localized disease who are not --- are not willing to undergo surgery or radiation and still want some sort of treatment might be selected to undergo androgen-deprivation if they don t want to the surveillance option. Very briefly, the pathophysiology of steroid synthesis and release: Gonadotropinreleasing hormones are released from the hypothalamus that activate receptors in the pituitary gland. And their LH is released through the systemic pathway that goes to the end organ, such as the testicles, but also the adrenal glands. There, testosterone is produced and acts on the end organ, here in our case the prostate, where testosterone is converted through the fal --- 5α-reductase into the dihydrotestosterone, binds the androgen receptor and translocates to the nucleus to induce survival advantage proliferation and other biologic phenotypes that are associated with cancer. The way we achieve castration is through surgical bilateral orchiectomy. This is still the standard of care in many other countries. It s cost effective. But here in this country, the majority of the patients undergo castration with LHRH agonists, such as leuprolide or LHRH antagonists such as degarelix. The way the LHRH agonists work is by overstimulating the hypothalamus. And after initial surge, the production of LHRH hormone is decreased and, therefore, down-streamed testosterone is suppressed. That means that there will be initial flare of the disease because there will be initial increase in testosterone. Therefore, these agents are combined with antiandrogens initially. On the other hand, degarelix as an antagonist inhibits the release of LH from the pituitary gland and, therefore, does not need to be combined with antiandrogens. Suppression of testosterone is achieved faster with degarelix, but in the long-term survival there is no clear benefit between these two agents. As already mentioned, in the United States, 90% of the patient s choose to undergo tes --- testosterone suppression with medical castration. Other options to castrate patients, especially for those who do not want to have medical castration is a single-agent antiandrogens, such as bicalutamide. The advantages are fewer hot flashes, less sexual dysfunction, less bone and muscle loss. And we will talk about this later in more detail. However, there is more gynecomastia. There is more pain in the breast. And which is probably more important, compared to LHRH agonists or antagonists, as well as bilateral orchiectomy, these antiandrogens as single agents
3 seem to be less effective clinically. And based on the negative feedback loops that I showed you before, antiandrogen therapy alone actually increases serum testosterone levels rather than decreasing them. The major adverse events with androgen-depris --- androgen-deprivation therapy to consider include: loss of libido, erectile dysfunction, decreased quality of life due to hot flashes, gynecomastia, fatigue, loss of muscle and bone mass, possibly cardiovascular disease, insulin-resistance and diabetes, psycholog --- psychological changes, and other. The question is if ADT is so effective in palliating pain and possibly also improving survival, why do we have to pay such special attention to long-term side --- adverse events? This is because of the paradox in prostate cancer where many men will be diagnosed with the disease, but only few will die of it. Given the PSA era and the controversies with screening, we have increasing numbers of patients who have been treated with localized disease --- diagnosed with localized disease, treated, and now have PSA-only recurrence without any additional signs of symptoms or disease burden. From published large trials and the series we know that only about 15% of patients who un --- who have a PSA-only relapse will go on to have metastatic disease. And maybe only a third of those will eventually die of the disease. This means that many of them will never progress to metastatic disease. A lot of them are otherwise relatively healthy and have a good quality of life. Therefore, we have to be very, very considerate and make efforts to focus on the different schedules and modes of ADT to minimize the decrease in quality of life that is associated with this treatment modality. One --- one of the ways where we try to minimize the adverse events of androgendeprivation is by giving it intermittently. The principle of intermittent ADT is one starts with induction, either giving a LHRH agonist for a set amount of time such as six or eight months or until a maximum PSA response is achieved. Typically since the response is thought to be achieved pretty rapidly, we combine it with antiandrogens. Once we have our maximum response, Lupron, for example, or leuprolide acetate, is stopped and the PSA is monitored regularly such as every four weeks. Then, at a certain pre-specified threshold, for example 10 ng/ml of PSA, the androgen-deprivation is restarted. The studies that I will show you have this cutoff for restarting ADT. But as we know in clinical practice, patients are much more anxious and urge the physician most of the time to start ADT sooner such as PSA levels of 1 or 2. The purpose of intermittent androgen-deprivation is to reduce the adverse effect of ADT during the off periods, such as: sexual dysfunction, vasomotor, hot flashes, loss of energy and fatigue, an --- and such. Based on the trials and the published data, we estimate that about 35-50% of the time that the patient is treated with this modality, he spends off androgen-deprivation and during those times it has been shown that libido and potency are regained and increase. Unfortunately, with each treatment break, the time to the next treatment becomes shorter and shorter, corre --- corresponding to biology that adjusts to the environment and becomes more resistant.
4 The largest trial published, Phase 3, supporting the use of -in --- intermittent androgendeprivation was a Canadian PR.7 trial where men with PSA-recurrent disease but no signs of metastatic disease were randomized to undergo either standard continuous androgen-deprivation therapy or intermittent ADT for eight months as mentioned before. Only those who actually achieved a PSA of less than 4 were enrolled further to undergo intermittent -adap ---- deprivation. People --- men who did not achieve maximum response, they were switched to the continuous arm. Once ADT was stopped, PSA was checked every two months and at the prespecified level of 10 was restarted. The control arm received the continuous androgen-deprivation therapy. The primary endpoint was to show that there is non-inferiority of intermittent ADT compared to continuous ADT in terms of overall survival. Almost 1,400 patients were enrolled with a median follow-up of 6.9 years. The median cycle of intermittent ADT given was only 2. But the range was up to 9. As shown here, overall survival was 8.8 years in the intermittent arm and 9.1 years in the continuous arm. Based on prespecified statistical requirements, it was concluded that intermittent ADT is non-inferior to continuous ADT in the setting of PSA-only relapse. If you look a little bit more in detail, we see that there were more prostate cancer-related deaths in the intermittent arm, but less unrelated death --- causes of death in the intermittent arm. As expected by some people, the time to castrate-resistant disease was actually prolonged in the intermittent arm in a statistically significant fashion; again, supporting the use of this modality. There were fewer hot flashes with intermittent treatment. There were other side effects, such as libido and potency that were also improved continu --- compared to the continuous arm. Therefore, in patients with PSA-only disease and no metastatic disease, one can use intermittent androgen-deprivation therapy to improve the quality of life of the patient without sacrificing the survival. Other modalities to improve quality of life as mentioned include monotherapy with antiandrogens, for example, with bicalutamide. Unfortunately, as I told you before, this treatment modality is inferior to castration in several clinical parameters including survival, time to PSA relapse, time to metastatic disease, and such. But the men will experience fewer hot flashes. But because of other effects of the antiandrogens, there is a higher incidence of gynecomastia, breast tenderness which might require even breast reduction surgery or radiation to the breasts. I will show you, as an example, two trials that randomized or compared high-dose bicalutamide of --- at 150 mg daily with more standard castration. In the first trial, the modality was compared to surgical castration. And it was shown the sus --- survival is inferior compared to castration if we only give bicalutamide. As expected, we had few -- - fewer hot flashes, better libido, less fatigue compared to the castration arm. Similar results when bicalutamide was compared to chemical castration with leuprolide, and as already expected, more gynecomastia and breast tenderness, fewer hot flashes, less fatigue, less bone loss, and better libido. Still, given the inferior clinical outcomes in terms of survival androgen monotherapy is not standard of care in metastatic patients because of these concerns.
5 Another modality that sometimes is used, although based on smaller trials, is the socalled sequential androgen blockade, also known as peripheral androgen blockade. The principle is to combine an antiandrogen that blocks the androgen receptor with a 5α-reductase inhibitor, such as flutamide, that inhibits the conversion of testosterone to the more potent dihydrotestosterone. We only have small reports from single centers, so there is no large randomized data. But based on the mechanism of action, which is in the peripheral tissue rather than centrally, zerum --- serum testosterone levels are not affected which may contribute to preserving potency. But similar to the antiandrogens alone, there has been reports of painful gynecomastia and men had to undergo breast reduction surgery for that. A major decrease in quality of life for the men that occurs with androgen-deprivation is sexual dysfunction. It develops in men on continuous ADT and starts with loss of libido within a few months followed by erectile dysfunction. Therefore, every physician starting ADT should be discussing with their patients sexual dysfunction prior to initiating the ADT. And some studies show consulting sex therapist might actually be of benefit for these patients. Sometimes, for example in the radiation combined setting, after short-term ADT, the erectile dysfunction can intru --- improve. But this might be incomplete or delayed and the patient should be aware of that. Alternative strategies to reduce erectile dysfunction, as mentioned, are intermittent ADT as shown in the P.R7 trial or antiandrogens alone. But more importantly, we have been getting more and more data on various other side effects and metabolic effects of androgen-deprivation therapy. Of the greatest concern so far was the effect of ADT on cardiovascular disease and mortality. Review of the literature shows there is no perspective randomized trial that compares the role of ADT to placebo with the primary end point of diabetes or cardiovascular risk or mortality. And given the clinical benefits of androgen-deprivation in prostate cancer, we will always have to weigh the potential harm of this modality with the possible risk of cardiovascular disease. What we can say to date is based on data based on large observational studies, retrospective studies of large randomized trials with other end points. And although conflicting, some of them indicated there might be a possible ---- increased risk of diabetes and cardiovascular disease with ADT. The mo --- the largest piece of data we have today is based on meta-analysis that was published last year in JAMA. And this study did not show an increased risk of cardiovascular death with a fairly long follow-up of 13 years. But it did show that prostate-specific and overall mortality was improved with ADT. So based on what we know today, the benefits of ADT do outweigh, in the majority of the patients, the cardiovascular risk that is potentially associated with this modality. Several trials have shown and examined the side effects of androgen-deprivation to be shown time dependent. Here, for example, the effects on bone marrow density on men and we see a correlation with time being on the treatment.
6 But more recently, we have had emerging evidence that hormonal changes and risk factors that contribute to metabolic syndrome might be modified and worsened by androgen-deprivation therapy. The pathophysiology is multifactorial. It is thought that increase in adipose tissue, fat mass, by ADT and the decrease of lean muscle mass results in a decreased glucose uptake in the muscle tissue. And there is increased release of hormones that are inflammatory in nature such as IL-6 [and] TNF-alpha from the adipose tissues and these two pathways taken together contribute to insulin resistance and metabolic dysregulation that is associated with ADT. It is thought that castration affects in the following ways: Metabolism and body composition. As I mentioned before, the lean body mass decreases, the adipose tissue increases, mainly in the subcutaneous adipose tissue. And these changes lead to decrease insulin sensitivity, hyperlipidemia. And they --- they occur fairly within the first one to two years of androgen-deprivation. It is thought that decreased serum testosterone levels affect muscle mass and increase adipose tissue. But also the fatigue that s associated with ADT leads to less exercise for the patients, which in turn also increases fat. Therefore, we do recommend regular exercise both endurance and resistance for our patients on ADT to help avoid or even sometimes reverse the body composition changes that we see to increase their fitness and energy levels. Encourage regular exercise regimens four to five times a week and consider monitoring with labs regularly for metabolic changes. The next few slides will just show you data from specific articles that examined the role of ADT to several parameters that contribute to the metabolic syndrome. Here, men who were undergoing androgen-deprivation shown in green in several bars were compared to controlled men with prostate cancer that did not receive ADT and normal controls. And we see abdominal obesity is significantly higher. Hypertriglyceridemia is more prevalent. And fasting glucose is higher compared to men with prostate cancer who do not undergo ADT. And these three parameters result in the metabolic syndrome. On the other hand, other factors that in the general population are thought to be associated with metabolic syndrome, such as hypertension and low HDL, do not seem to be affected by the androgen-deprivation. This other paper confirms that we have a significant increase in fasting glucose levels, hyperinsulinemia as a sign of insulin-resistance, as well as increase in the HOMA insulin resistance score, which is a multivariable score, in patients undergoing ADT shown here in the gray bars. Here represented in fasting glucose levels greater than 126 occurring in 40% of men with ADT compared to controls with prostate cancer or healthy men.
7 And as a resulting factor hyperinsulinemia in men who receive at least three months of ADT. Abdominal obesity, hypertriglyceridemia, and hyperglycemia. But not LDL [speaker intended to say HDL ] or hypertension, are the factors that contribute to metabolic syndrome in men with prostate cancer. Thank you very much. This concludes the first part of this talk, and I welcome all of your feedback.
Metastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationManipulating Hormones: Androgen Suppression in Prostate Cancer Patients
Focus on CME at the University of Queen s ManitobaUniversity Manipulating Hormones: Androgen Suppression in ostate Cancer Patients By D. Robert Siemens, MD, FRCSC Case A 62-year old man presents with complaints
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationPatient & Family Guide 2015 Hormone Therapy for Prostate Cancer
Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer www.nshealth.ca Hormone Therapy for Prostate Cancer What is the prostate? The prostate is one of the male sex glands. It makes seminal fluid
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationAndrogen Deprivation Therapy Its impact and the nursing role. Jane Thacker Uro-Oncology Nurse Specialist
Androgen Deprivation Therapy Its impact and the nursing role Jane Thacker Uro-Oncology Nurse Specialist Overview of content To gain an understanding of ADT (androgendeprivation therapy) and why and how
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationLUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology
LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationProstate Cancer Case Study 2. Medical Student Case-Based Learning
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationHormonotherapy of advanced prostate cancer
Annals of Oncology 16 (Supplement 4): iv80 iv84, 2005 doi:10.1093/annonc/mdi913 Hormonotherapy of advanced prostate cancer P. Pronzato & M. Rondini Department of Oncology, Felettino Hospital, La Spezia,
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationreviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
More informationThe Current State of Hormonal Therapy for Prostate Cancer
The Current State of Hormonal Therapy for Prostate Cancer The Current State of Hormonal Therapy for Prostate Cancer Beth A. Hellerstedt, MD; Kenneth J. Pienta, MD Dr. Hellerstedt is Fellow, Division of
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More information17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom
My Biases Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom I am a member of the specialist group of the Prostate
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationUrologic Oncology: Seminars and Original Investigations 30 (2012) 3 15
Urologic Oncology: Seminars and Original Investigations 30 (2012) 3 15 Review article The multi-disciplinary management of high-risk prostate cancer Jonathan C. Picard, M.D. a, *, Ali-Reza Golshayan, M.D.
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationClinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationCommunity care of Prostate Cancer. Shaun Costello Southern Cancer Network
Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationSAMPLE ONLY. Your Health Matters. Advanced Prostate Cancer and its Treatment A Patient Guide. Please order from Documents and Media: 415/
Your Health Matters Advanced Prostate Cancer and its Treatment A Patient Guide UCSF Genitourinary Medical Oncology Program Charles Ryan, MD, UCSF Patient Advocates Please order from Documents and Media:
More informationPCa Commentary. Seattle Prostate Institute CONTENTS. Volume 71 September-October 2011
Volume 71 September-October 2011 PCa Commentary CONTENTS PERMANENT SEED BRACHYTHERAPY FOR HIGH- RISK PROSTATE CANCER: 1 CABOZANTINIB: Startling Responses Reported at June ASCO Meeting in Metastatic Castrate
More informationTESTOSTERONE DEFINITION
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
More informationthrough the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.
Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationHormone therapy for prostate cancer
The Clatterbridge Cancer Centre NHS Foundation Trust Hormone therapy for prostate cancer General information A guide for patients and carers Contents What is hormone therapy?... 1 How does hormone therapy
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationRadiation Therapy. External Beam Radiation Therapy
Radiation Therapy Radiation therapy is a non-invasive treatment for prostate cancer that uses x-rays or gamma-rays to eradicate prostate cancer cells. There are several forms of radiation therapy that
More informationAndrogen Deprivation Therapy (ADT) Following Recurring Prostate Cancer Or When Androgen Deprivation Becomes The Necessary Therapy
Androgen Deprivation Therapy (ADT) Following Recurring Prostate Cancer Or When Androgen Deprivation Becomes The Necessary Therapy By Prostate Cancer Patient and Activist/Mentor Charles (Chuck) Maack with
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationLecture 10: Hormonal agents
Lecture 10: Hormonal agents The survival and proliferation (growth) of some cancer cells is dependent on the action of steroid hormones. Early stage breast cancer and early stage prostate cancer are the
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationRationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationPROSTATE CANCER CONTENT CREATED BY. Learn more at
PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationFIRMAGON/DEGARELIX. Compiled by Charles (Chuck) Maack Prostate Cancer Activist/Mentor
FIRMAGON/DEGARELIX The Advantage of this GnRH/LHRH antagonist over that of GnRH/LHRH agonists particularly when administered to patients with known prostate cancer metastases Compiled by Charles (Chuck)
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationProstate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy).
Thanks to: The Medical Educator Consortium Luis Raez, MD, Florida International University 15th ed. Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Mayer Fishman,
More informationClinical Practice Considerations for Androgen Deprivation Therapy
Published as a Promotional Supplement to September 2016 Clinical Practice Considerations for Androgen Deprivation Therapy Expert Panel Discussion Sponsored by Clinical Practice Considerations for Androgen
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationGuidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer
Peterborough City Hospital Department of Urology Guidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer Hormonal Therapy - How does it work? Prostate Cancer relies on the presence
More informationChallenges in the management of metastatic prostate cancer
Oncology 323 Challenges in the management of metastatic prostate cancer A significant number of men with prostate cancer will be elderly. Although some of the issues they face will be the same as their
More informationCurrent UW/SCCA GU Oncology Clinical Trials Updated 01/25/2010
Neoadjuvant Non-Metastatic Current UW/SCCA GU Oncology Clinical Trials Gleason Stage PSA Design Type Route Active surveillance PASS 3 Active Surveillance for pts w/ Active T1 2 NA Visit Seattle q6 months
More informationAndrogen Deprivation Therapy A Question of Timing
Androgen Deprivation Therapy A Question of Timing James Johnston BSc MBChB FRACS (Urol) Disclosure 1 OUTLINE History Watchful waiting Node positive patient Recurrence Intermittent Androgen Suppression
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationTargeting GPCRs for Cancer Therapy 03/11/2014
Targeting GPCRs for Cancer Therapy 03/11/2014 G Protein Coupled Receptors Actually 4% of the human genome GPCR dysfunction contributes to some of the most prevalent human diseases GPCRs represent 60% of
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationPCa Commentary. Volume 74 March April 2012
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 74 March April 2012 CONTENTS 1 AN ALTERNATIVE TO LUPRON 2 MDV3100 Phase III AFFIRM Trial Demonstrates
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationMedical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationMarketing Authorisation Holder Applicant Invented name. Route of administration. Content (concentration) Member State. l form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT AND MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 1 Member State Marketing Authorisation
More informationFinal Appraisal Report. Ferring Pharmaceuticals Ltd. Advice No: 2109 December Recommendation of AWMSG
Final Appraisal Report Degarelix (Firmagon ) for the treatment of advanced hormone-dependent prostate cancer Ferring Pharmaceuticals Ltd Advice No: 2109 December 2009 Recommendation of AWMSG Degarelix
More informationTHE FACTS, DOC, JUST THE FACTS
November 1997 April 2004 (Revised) THE FACTS, DOC, JUST THE FACTS I have just reviewed a timely article. Here are some quotes and paraphrases from it: Recently, a number of urologists have begun to question
More information